PL
TVTX icon

Parkwood LLC’s Travere Therapeutics TVTX Stock Holding History

Parkwood LLC’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-16,704
Closed -$351K – 178
2022
Q4 		$351K Buy
16,704
+1,458
+10% +$30.9K 0.05% 125
2022
Q3 		$376K Buy
15,246
+532
+4% +$13.7K 0.06% 123
2022
Q2 		$357K Sell
14,714
-2,983
-17% -$75K 0.06% 123
2022
Q1 		$456K Buy
+17,697
New +$470K 0.07% 102

Other funds holding TVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Parkwood LLC's TVTX Position: Q1 2023 in Review

Parkwood LLC sold out of Travere Therapeutics (TVTX) in Q1 2023, closing a stake of 16,704 shares — an estimated $351K sold.

Parkwood LLC first reported a position in TVTX in Q1 2022 and held it in 4 quarters. The position peaked at $456K in Q1 2022. 174 funds tracked by Wall St. Rank hold TVTX as of Q1 2023.

  • Parkwood LLC reported no remaining Travere Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Parkwood LLC sold 16,704 Travere Therapeutics shares in Q1 2023, an estimated $351K.
  • Parkwood LLC first reported a position in Travere Therapeutics in Q1 2022 and held it in 4 quarters.
  • Parkwood LLC's Travere Therapeutics position peaked at $456K in Q1 2022.
  • 174 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2023.

Based on Parkwood LLC's 13F filing for Q1 2023, filed 15 May 2023.